What does Dishman Carbogen do?

Dishman Carbogen Amcis Ltd provides Contract Research and Manufacturing Services in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of ₹716 Cr and a net profit of ₹43 Cr, with a market cap of ₹4,226 Cr.

Overview:<BR>Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) within the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History:<BR>The company was incorporated as Carbogen Amcis (India) Limited in 2007 and later changed its name to Dishman Carbogen Amcis Limited on March 27, 2017. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 716 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 43 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 4,226 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 191.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.32<BR>- Return on Equity: 0.38%<BR>- Price to Book: 0.73<BR><BR>Contact Details:<BR>Address: Dishman Corporate House, Iscon-Bopal Road Ambli Ahmedabad Gujarat : 380058<BR>Tel: 91-2717-400102/124<BR>Email: grievance@dishmangroup.com<BR>Website: htts://imdcal.com

Has Dishman Carbogen declared dividend?

Dishman Carbogen Amcis Ltd has declared a 10% dividend, amounting to ₹0.2 per share, with an ex-date of September 12, 2019. However, there have been no dividends declared since then, resulting in a 0% dividend return across multiple periods despite significant price returns.

Dishman Carbogen Amcis Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 0.2<BR>- Ex-date: 12 Sep 19<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -0.48%, the dividend return was 0%, resulting in a total return of -0.48%.<BR><BR>Over the past year, the price return was 85.25%, with a dividend return of 0%, leading to a total return of 85.25%.<BR><BR>In the last 2 years, the price return was 116.96%, while the dividend return remained at 0%, culminating in a total return of 116.96%.<BR><BR>For the 3-year period, the price return was 124.29%, with a dividend return of 0%, resulting in a total return of 124.29%.<BR><BR>In the 4-year period, the price return was 27.47%, and the dividend return was 0%, leading to a total return of 27.47%.<BR><BR>Over the last 5 years, the price return was 273.97%, with a dividend return of 0%, resulting in a total return of 273.97%.<BR><BR>Overall, Dishman Carbogen has declared a dividend in the past, but there have been no dividends declared since then, as indicated by the 0% dividend return across multiple periods. The company has shown significant price returns over the years, particularly in the 5-year period, despite the absence of recent dividends.

Who are the peers of the Dishman Carbogen?

Dishman Carbogen's peers include Aarti Drugs, Sequent Science, Hikal, Unichem Labs, RPG LifeScience, Gujarat Themis Bio, Orchid Pharma, Gufic BioScience, and Advanced Enzyme. RPG LifeScience shows excellent management risk and the highest 1-year return at 44.57%, while Orchid Pharma has the lowest return at -34.27%.

Peers: The peers of Dishman Carbogen are Aarti Drugs, Sequent Scien., Hikal, Unichem Labs., RPG LifeScience., Guj. Themis Bio., Orchid Pharma, Gufic BioScience, and Advanced Enzyme.<BR><BR>Quality Snapshot: Excellent management risk is observed at RPG LifeScience, while Good management risk is found at Aarti Drugs, Hikal, Guj. Themis Bio., Gufic BioScience, and Advanced Enzyme, and the rest have Average or Below Average management risk. Growth is Below Average for Aarti Drugs, Sequent Scien., Hikal, RPG LifeScience, Guj. Themis Bio., Orchid Pharma, and Advanced Enzyme, while Average growth is seen at Unichem Labs. and Gufic BioScience, and the rest have Below Average growth. Capital Structure is Excellent for RPG LifeScience, Guj. Themis Bio., Gufic BioScience, and Advanced Enzyme, Good for Aarti Drugs and Unichem Labs., Average for Hikal, and Below Average for Sequent Scien., Dishman Carbogen, Orchid Pharma, and Zota Health Care.<BR><BR>Return Snapshot: RPG LifeScience has the highest 1-year return at 44.57%, while Orchid Pharma has the lowest at -34.27%, with Dishman Carbogen's own 1-year return at 57.24% being significantly higher than both. Additionally, Orchid Pharma and Advanced Enzyme have negative six-month returns.

Who are in the management team of Dishman Carbogen?

As of March 2022, the management team of Dishman Carbogen includes Janmejay R Vyas (Chairman), Deohooti J Vyas (Whole-time Director), Arpit J Vyas (Managing Director & CFO), and several independent directors, along with a Company Secretary. This team oversees the company's operations and governance.

As of March 2022, the management team of Dishman Carbogen includes the following individuals:<BR><BR>1. Janmejay R Vyas - Chairman (Non-Executive)<BR>2. Deohooti J Vyas - Whole-time Director<BR>3. Arpit J Vyas - Managing Director & CFO<BR>4. Sanjay S Majmudar - Independent Director<BR>5. Ashok C Gandhi - Independent Director<BR>6. Subir Kumar Das - Independent Director<BR>7. Rajendra S Shah - Independent Director<BR>8. Shrima Dave - Company Secretary & Compliance Officer<BR>9. Maitri K Mehta - Independent Director<BR><BR>This team comprises a mix of executive and independent directors, along with a compliance officer, overseeing the company's operations and governance.

Who are the top shareholders of the Dishman Carbogen?

The top shareholders of Dishman Carbogen include Adimans Technologies LLP with 59.32%, individual investors with 25.31%, and Mukul Mahavir Agrawal holding 5.5%. Additionally, foreign institutional investors hold 9.49%, and mutual funds have a combined stake of 1.06%, with no pledged promoter holdings reported.

The top shareholders of Dishman Carbogen include the promoters, with Adimans Technologies LLP holding the highest stake at 59.32%. Additionally, individual investors collectively own 25.31% of the company. Among public shareholders, Mukul Mahavir Agrawal is notable with a holding of 5.5%. The company also has 61 foreign institutional investors (FIIs) holding 9.49% and 6 mutual fund schemes with a combined holding of 1.06%. There are no pledged promoter holdings reported.

How big is Dishman Carbogen?

As of 24th July, Dishman Carbogen Amcis Ltd has a market capitalization of 4,061.00 Cr, with net sales of 2,711.50 Cr and a net profit of 3.24 Cr for the latest four quarters. The balance sheet as of March 2024 shows shareholder's funds of 5,627.50 Cr and total assets of 9,570.62 Cr.

As of 24th July, Dishman Carbogen Amcis Ltd has a market capitalization of 4,061.00 Cr, categorizing it as a Small Cap company.<BR><BR>For the latest four quarters, the company reported net sales of 2,711.50 Cr and a net profit of 3.24 Cr.<BR><BR>As of March 2024, the balance sheet shows shareholder's funds amounting to 5,627.50 Cr and total assets of 9,570.62 Cr.

When is the next results date for Dishman Carbogen?

Dishman Carbogen is scheduled to declare its results on 04 November 2025.

Dishman Carbogen is scheduled to declare its results on 04 November 2025.

Are Dishman Carbogen latest results good or bad?

Dishman Carbogen's latest results show strong profitability with a net profit increase of 178.81% quarter-on-quarter, but revenue fell by 7.82% sequentially and 17.29% year-on-year, raising concerns about sustainability. Investors should closely monitor revenue trends for future prospects.

Dishman Carbogen's latest results present a mixed picture. On one hand, the company achieved a significant increase in net profit, which rose to ₹65.27 crores in Q2 FY26, marking a remarkable 178.81% increase quarter-on-quarter and a 97.25% increase year-on-year. This surge in profitability is complemented by an impressive operating margin of 22.81%, the highest in recent history, indicating strong operational efficiency.<BR><BR>However, the revenue side tells a different story. Net sales fell to ₹652.65 crores, reflecting a decline of 7.82% sequentially and 17.29% year-on-year. This drop represents the lowest quarterly sales figure in recent periods, raising concerns about the company's revenue sustainability and overall business momentum.<BR><BR>In summary, while the profitability metrics are strong and suggest effective cost management, the significant decline in revenue raises questions about the company's ability to maintain this level of profit in the future. Investors may want to monitor the company's revenue trends closely in the coming quarters to gauge its long-term prospects.

Is Dishman Carbogen overvalued or undervalued?

As of November 6, 2025, Dishman Carbogen is considered fairly valued with a PE ratio of 28.07, an EV to EBITDA of 10.39, and a Price to Book Value of 0.72, outperforming the Sensex with a 37.05% return over the past year.

As of 6 November 2025, Dishman Carbogen's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently considered fairly valued. Key ratios include a PE ratio of 28.07, an EV to EBITDA of 10.39, and a Price to Book Value of 0.72. <BR><BR>In comparison to its peers, Dishman Carbogen's PE ratio is lower than that of Sun Pharma, which stands at 35.02, and significantly lower than Divi's Lab at 79.09. However, it is on par with Cipla, which has a PE of 22.27, and Dr. Reddy's Labs at 17.42. Notably, Dishman Carbogen has outperformed the Sensex over the past year with a return of 37.05% compared to the Sensex's 3.65%, reinforcing its current valuation status.

How has been the historical performance of Dishman Carbogen?

Dishman Carbogen's historical performance shows steady growth in net sales from INR 2,140.69 crore in March 2022 to INR 2,711.50 crore in March 2025, with improved profitability indicators, including a profit after tax of INR 3.24 crore in March 2025. Total liabilities and assets increased, reflecting a stronger financial position, while cash flow from operations remained stable.

Answer:<BR>The historical performance of Dishman Carbogen shows a fluctuating trend in key financial metrics over the years leading up to March 2025.<BR><BR>Breakdown:<BR>Dishman Carbogen's net sales have shown a steady increase from INR 2,140.69 crore in March 2022 to INR 2,711.50 crore in March 2025. The total operating income followed a similar trend, rising from INR 2,140.69 crore in March 2022 to INR 2,711.50 crore in March 2025. However, the total expenditure, excluding depreciation, increased from INR 1,809.32 crore in March 2022 to INR 2,242.56 crore in March 2025, impacting the operating profit, which saw a rise to INR 468.94 crore in March 2025 from INR 331.37 crore in March 2022. Despite this, the profit before tax turned positive at INR 19.31 crore in March 2025 after being negative in the previous years. The profit after tax also improved to INR 3.24 crore in March 2025 from a loss of INR 153.45 crore in March 2024. On the balance sheet, total liabilities increased to INR 9,986.34 crore in March 2025 from INR 8,634.20 crore in March 2022, while total assets rose to INR 9,986.34 crore in March 2025, indicating a growth in the company's financial position. Cash flow from operating activities remained relatively stable, with INR 375 crore in March 2025, while net cash inflow was recorded at INR 76 crore for the same period. Overall, Dishman Carbogen has shown signs of recovery and growth in its financial performance over the past few years.

Should I buy, sell or hold Dishman Carbogen?

Is Dishman Carbogen technically bullish or bearish?

As of December 2, 2025, the market trend for Dishman Carbogen has shifted to mildly bearish, indicated by bearish MACD readings and Bollinger Bands on the weekly chart, despite some short-term support from daily moving averages.

As of 2 December 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, supported by the weekly and monthly MACD readings, both indicating a bearish momentum. The Bollinger Bands show a bearish signal on the weekly chart, while the daily moving averages are mildly bullish, suggesting some short-term support. The KST and OBV are also mildly bearish on the weekly timeframe. Overall, the combination of these indicators points to a bearish sentiment in the current market environment for Dishman Carbogen.

Which are the latest news on Dishman Carbogen?

Why is Dishman Carbogen falling/rising?

As of 03-Dec, Dishman Carbogen Amcis Ltd's stock price is rising to 237.40, indicating a potential shift in market sentiment after recent declines. However, long-term performance remains weak, with significant declines over the past month and year-to-date, alongside reduced investor participation.

As of 03-Dec, Dishman Carbogen Amcis Ltd's stock price is rising, currently at 237.40, reflecting a change of 0.7 (0.3%) upwards. This increase follows a trend reversal after four consecutive days of decline, indicating a potential shift in market sentiment. Additionally, the stock has outperformed its sector by 0.31% today, suggesting a relative strength compared to its peers.<BR><BR>Despite the recent rise, the stock has shown weak performance over longer periods, with a decline of 18.60% over the past month and a year-to-date drop of 12.40%. The stock is currently trading below its moving averages across various time frames, which typically indicates bearish sentiment. Furthermore, there has been a notable decrease in investor participation, with delivery volume falling by 25.07% against the 5-day average, which may signal reduced interest from investors.<BR><BR>On a positive note, the company has reported strong financial results in the last three consecutive quarters, with a significant increase in profits and a high operating profit margin. The stock is also trading at a discount compared to its peers, which may attract some investors looking for value. However, the long-term fundamentals remain a concern, as indicated by a low average Return on Capital Employed (ROCE) and a high Debt to EBITDA ratio, which could deter potential buyers.<BR><BR>In summary, while the stock is experiencing a short-term rise, the overall context suggests mixed signals, with strong recent performance overshadowed by longer-term weaknesses and declining investor participation.